Biological mechanisms of action of novel C-10 non-acetal trioxane dimers in prostate cancer cell lines

被引:59
作者
Alagbala, Adebusola A.
McRiner, Andrew J.
Borstnik, Kristina
Labonte, Tanzina
Chang, Wonsuk
D'Angelo, John G.
Posner, Gary H.
Foster, Barbara A.
机构
[1] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
[2] Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA
[3] Johns Hopkins Univ, Malaria Res Inst, Baltimore, MD 21218 USA
关键词
D O I
10.1021/jm060803i
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The mechanisms of action of three C-10 non-acetal trioxane dimers (TDs) were examined in human (LNCaP) and mouse (TRAMP-C1A and -C2H) prostate cancer cell lines. 1 (AJM3/23), 2 (GHP-TM-III-07w), and 3 (GHP-KB-06) inhibited cell growth with 3 being the most potent in C1A (GI(50) = 18.0 nM), C2H (GI(50) = 17.0 nM), and LNCaP (GI(50) = 17.9 nM) cells. In comparison to a standard cytotoxic agent such as doxorubicin (GI(50) = 45.3 nM), 3 (GI(50) = 17.9 nM) inhibited LNCaP cell growth more potently. TDs induced G(0)/G(1) cell cycle arrest in LNCaP cells and decreased cells in the S phase. These changes correlated with modulation of G(1) phase cell cycle proteins including decreased cyclin D1, cyclin E, and cdk2 and increased p21(waf1) and p27(Kip1). TDs also promoted apoptosis in LNCaP cells with increased expression of proapoptotic bax. These results demonstrate that TDs are potentially useful agents that warrant further preclinical development for treatment of prostate cancer.
引用
收藏
页码:7836 / 7842
页数:7
相关论文
共 48 条
[1]  
Aaltomaa S, 1999, PROSTATE, V39, P8
[2]   CYCLIN D1 IS A NUCLEAR-PROTEIN REQUIRED FOR CELL-CYCLE PROGRESSION IN G(1) [J].
BALDIN, V ;
LUKAS, J ;
MARCOTE, MJ ;
PAGANO, M ;
DRAETTA, G .
GENES & DEVELOPMENT, 1993, 7 (05) :812-821
[3]   Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer [J].
Culine, S ;
Kattan, J ;
Zanetta, S ;
Theodore, C ;
Fizazi, K ;
Droz, JP .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (05) :470-474
[4]  
Dawson R.M. C., 2002, DATA BIOCH RES
[5]   Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues [J].
de Marval, PLM ;
Macias, E ;
Rounbehler, R ;
Sicinski, P ;
Kiyokawa, H ;
Johnson, DG ;
Conti, CJ ;
Rodriguez-Puebla, ML .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (17) :7538-7547
[6]   MICE LACKING P21(C/P1/WAF1) UNDERGO NORMAL DEVELOPMENT, BUT ARE DEFECTIVE IN G1 CHECKPOINT CONTROL [J].
DENG, CX ;
ZHANG, PM ;
HARPER, JW ;
ELLEDGE, SJ ;
LEDER, P .
CELL, 1995, 82 (04) :675-684
[7]   FLOW CYTOMETRIC MEASUREMENT OF TOTAL DNA CONTENT AND INCORPORATED BROMODEOXYURIDINE [J].
DOLBEARE, F ;
GRATZNER, H ;
PALLAVICINI, MG ;
GRAY, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (18) :5573-5577
[8]   Molecular modes of action of artesunate in tumor cell lines [J].
Efferth, T ;
Sauerbrey, A ;
Olbrich, A ;
Gebhart, E ;
Rauch, P ;
Weber, HO ;
Hengstler, JG ;
Halatsch, ME ;
Volm, M ;
Tew, KD ;
Ross, DD ;
Funk, JO .
MOLECULAR PHARMACOLOGY, 2003, 64 (02) :382-394
[9]   mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether [J].
Efferth, T ;
Olbrich, A ;
Bauer, R .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (04) :617-623
[10]  
Foster BA, 1997, CANCER RES, V57, P3325